Product: IL8 Antibody
Catalog: DF6998
Source: Rabbit
Application: WB, IHC, ELISA(peptide)
Reactivity: Human
Mol.Wt.: 11kD; 11kD(Calculated).
Uniprot: P10145
RRID: AB_2838954

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, ELISA(peptide) 1:20000-1:40000
*The optimal dilutions should be determined by the end user.
Reactivity:
Human
Clonality:
Polyclonal
Specificity:
IL8 Antibody detects endogenous levels of total IL8.
RRID:
AB_2838954
Cite Format: Affinity Biosciences Cat# DF6998, RRID:AB_2838954.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

(Ala-IL-8)77; (Ser-IL-8)72; 9E3; Beta thromboglobulin like protein; C-X-C motif chemokine 8; CEF-4; chemokine, CXC motif, ligand 8; CXCL8; Emoctakin; GCP-1; GCP/IL-8 protein I; GCP/IL-8 protein II; GCP/IL-8 protein III; GCP/IL-8 protein IV; GCP/IL-8 protein V; GCP/IL-8 protein VI; GCP1; Granulocyte chemotactic protein 1; IL-8; IL-8(1-77); IL-8(9-77); IL8; IL8/NAP1 form I; IL8/NAP1 form II; IL8/NAP1 form III; IL8/NAP1 form IV; IL8/NAP1 form V; IL8/NAP1 form VI; IL8_HUMAN; Inteleukin 8; LECT; LUCT; Lymphocyte-derived neutrophil-activating factor; LYNAP; MDNCF; MDNCF-b; MDNCF-c; MONAP; Monocyte-derived neutrophil chemotactic factor; Monocyte-derived neutrophil-activating peptide; NAF; NAP-1; NAP1; Neutrophil activating peptide 1; Neutrophil activating protein 1; Neutrophil-activating factor; Neutrophil-activating protein 1; Protein 3 10C; Protein 3-10C; SCYB8; Small inducible cytokine subfamily B member 8; T cell chemotactic factor; T-cell chemotactic factor; TSG1;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Description:
The protein encoded by this gene is a member of the CXC chemokine family. This chemokine is one of the major mediators of the inflammatory response. This chemokine is secreted by several cell types. It functions as a chemoattractant, and is also a potent angiogenic factor. This gene is believed to play a role in the pathogenesis of bronchiolitis, a common respiratory tract disease caused by viral infection. This gene and other ten members of the CXC chemokine gene family form a chemokine gene cluster in a region mapped to chromosome 4q.
Sequence:
MTSKLAVALLAAFLISAALCEGAVLPRSAKELRCQCIKTYSKPFHPKFIKELRVIESGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Chicken
71
Pig
0
Horse
0
Bovine
0
Sheep
0
Dog
0
Xenopus
0
Zebrafish
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

IL-8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells, but not monocytes. It is also involved in neutrophil activation. It is released from several cell types in response to an inflammatory stimulus. IL-8(6-77) has a 5-10-fold higher activity on neutrophil activation, IL-8(5-77) has increased activity on neutrophil activation and IL-8(7-77) has a higher affinity to receptors CXCR1 and CXCR2 as compared to IL-8(1-77), respectively.

PTMs:

Several N-terminal processed forms are produced by proteolytic cleavage after secretion from at least peripheral blood monocytes, leukcocytes and endothelial cells. In general, IL-8(1-77) is referred to as interleukin-8. IL-8(6-77) is the most promiment form.

Citrullination at Arg-27 prevents proteolysis, and dampens tissue inflammation, it also enhances leukocytosis, possibly through impaired chemokine clearance from the blood circulation.

Subcellular Location:

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Homodimer.

Family&Domains:

Belongs to the intercrine alpha (chemokine CxC) family.

Research Fields

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway.   (View pathway)

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Infectious diseases: Bacterial > Epithelial cell signaling in Helicobacter pylori infection.

· Human Diseases > Infectious diseases: Bacterial > Shigellosis.

· Human Diseases > Infectious diseases: Bacterial > Salmonella infection.

· Human Diseases > Infectious diseases: Bacterial > Pertussis.

· Human Diseases > Infectious diseases: Bacterial > Legionellosis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Malaria.

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Cancers: Specific types > Bladder cancer.   (View pathway)

· Human Diseases > Immune diseases > Rheumatoid arthritis.

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > RIG-I-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

References

1). Zhao M et al. HIF-1α/JMJD1A signaling regulates inflammation and oxidative stress following hyperglycemia and hypoxia-induced vascular cell injury. Cell Mol Biol Lett 2021 Sep 3;26(1):40. (PubMed: 34479471) [IF=8.702]

Application: WB    Species: Human    Sample: HUVECs

Fig. 3 Effects of inhibition of HIF-1α on expression of inflammation after hyperglycemic and hypoxia. a Cells were treated with glucose (25 mM) or with combined exposure to high glucose and hypoxia for 6, 12, 24, and 48 h. Exposure to glucose alone or combined stimulation with hypoxia significantly increased gene expression of HIF-1α. b Cells were treated with KC7F2 (10 µM) or si-HIF-1α for 48 h following combined stimulation, and IL-6, IL-8, ICAM-1, MCP-1, and c HIF-1α levels were analyzed. The relative density of IL-6, IL-8, ICAM-1, and MCP-1 (d) was normalized according to GAPDH expression. Importantly, the downregulation of HIF-1α decreased the secretion of IL-6, IL-8, ICAM-1 and MCP-1 based on ELISA and qRT-PCR assays (e–f). n = 3; *p < 0.05 and **p < 0.01 vs. DMSO. DMSO-treated cells, DMSO; HIF-1α inhibitors KC7F2 (10 µM)-treated cells, KC7F2 (10 µM); si-HIF-1α, small interfering RNA HIF-1α; HG, high glucose; HG + Hypoxia, combined stimulus with high glucose and hypoxia; NG, control

Application: WB    Species: human    Sample: HUVECs

Fig. 3 | Efects of inhibition of HIF-1α on expression of infammation after hyperglycemic and hypoxia.b Cells were treated with KC7F2 (10 µM) or si-HIF-1α for 48 h following combined stimulation, and IL-6, IL-8, ICAM-1, MCP-1, and c HIF-1α levels were analyzed. The relative density of IL-6, IL-8,ICAM-1, and MCP-1 (d) was normalized according to GAPDH expression.

2). Qin X et al. An Extracellular Matrix-Mimicking Hydrogel for Full Thickness Wound Healing in Diabetic Mice. Macromol Biosci 2018 Jul;18(7):e1800047 (PubMed: 29737012) [IF=5.859]

Application: IHC    Species: rat    Sample: inflammatory cell

Figure 6. |Immunohistochemical staining of a) IL-8 and b) MCP-1 in the wound bed on day 3, 7, and 14. Scale bars represent 100 µm. c) Semiquantitative analysis of IL-8 and MCP-1, double-blind analysis by using a four-point scale (0, no positive cells; 1, low number of positive cells; 2, moderate number of positive cells; and 3, high number of positive cells). The level of IL-8 in the HA-GEL group was significantly lower than that in the other two groups at day 7 (p < 0.05). On day 3, both alginate and HA-GEL groups could significantly reduce the expression of MCP-1. On day 7, the level of MCP-1 in the HA-GEL group remained significantly lower than that in the alginate group and control.

3). Lin L et al. BML-111 inhibits EMT, migration and metastasis of TAMs-stimulated triple-negative breast cancer cells via ILK pathway. Int Immunopharmacol 2020 May 30;85:106625. (PubMed: 32485356) [IF=5.714]

Application: IHC    Species: mouse    Sample: tumor

Fig.7. The inhibitory effect of BML-111 on the tumor growth of 4T1-MIND model mice in vivo (A) Representative images of the tumor tissue dissected from 4T1-MIND model mice. *P = 0.0271 BML-111 group vs. control group. (F) The expression of IL-8 in tumor cells and stroma of BML-111 group was compared with that in control group. Scale bar, 200 μm. ****P < 0.0001.

4). Li J et al. Transcriptional Profiling Reveals the Regulatory Role of CXCL8 in Promoting Colorectal Cancer. Front Genet 2020 Jan 21;10:1360 (PubMed: 32038715) [IF=4.599]

Application: IHC    Species: human    Sample: tumor

FIGURE 3 | Expression levels of CXCL8 in the clinical cohort. (A) The levels of CXCL8 mRNA in the normal (N = 81), colorectal cancer (CRC)-early stage (N = 44)and CRC-advanced stage (N = 37) groups. (B) The levels of CXCL8 protein in normal (N = 87), CRC-early stage (N = 48), and CRC-advanced stage (N = 39)groups. (C) Immunohistochemical staining of normal, CRC-early stage and CRC-advanced stage groups.

5). Zhang T et al. Interaction with tumor‑associated macrophages promotes PRL‑3‑induced invasion of colorectal cancer cells via MAPK pathway‑induced EMT and NF‑κB signaling‑induced angiogenesis. Oncol Rep 2019 Mar 7 (PubMed: 30864736) [IF=4.136]

Application: WB    Species: mouse    Sample: TAMs

Figure 2. |PRL‑3‑induced activation of IL‑6 and IL‑8 by initiating JNK and ERK pathways in TAMs. (A) After co‑culture with colorectal cancer cells, IL‑6, IL‑8, p‑JNK, and p‑ERK levels in TAMs were examined using western blot assays.

6). Wang P et al. Screening of immunosuppressive factors for biomarkers of breast cancer malignancy phenotypes and subtype-specific targeted therapy. PeerJ 2019 Jun 27;7:e7197 (PubMed: 31293831) [IF=3.061]

Application: WB    Species: human    Sample: T549 and MDA-MB-231 cell; MCF7 and T47D cell

Figure 8| qRT-PCR and western blot results. (A, B) qRT-PCR results showed that CD274 and IL8 were upregulated in the basal-like breast cancer cell lines BT549 and MDA-MB-231 (p < 0.0001). Similar to the qRT-PCR results, the western blot analysis (C–E) indicated that CD274 and IL8 protein were increased in the BT549 and MDA-MB-231 cell lines compared to the MCF7 and T47D cell lines. P < 0.001, p < 0.01, and p < 0.05

7). Huang SP et al. Evaluation of the Mechanism of Jiedu Huazhuo Quyu Formula in Treating Wilson’s Disease-Associated Liver Fibrosis by Network Pharmacology Analysis and Molecular Dynamics Simulation. Evid Based Complement Alternat Med 2022 Jun 6;2022:9363131. (PubMed: 35707473)

8). Zhao B et al. Prostatic fluid exosome-mediated microRNA-155 promotes the pathogenesis of type IIIA chronic prostatitis. Transl Androl Urol 2021 May;10(5):1976-1987. (PubMed: 34159078)

Application: IF/ICC    Species: Rat    Sample: prostate tissue

Figure 4 Prostatic fluid exosomes promoted inflammation in prostate tissue. (A) Representative HE-staining images of prostate tissue in SD rats injected with normal saline, NC exosomes, prostatic fluid exosomes of CP/CPPS-A patients, and ultrasound-treated prostatic fluid exosomes of CP/CPPS-A patients. (B) Results of prostate tissue in different groups measured by MPO activity assay. (C–E) Expression of IL-8 (TRITC secondary antibodies), TNF-α (FITC secondary antibodies), and iNOS (TRITC secondary antibodies) in different groups of prostate tissue observed under a fluorescence microscope, scale bar =100 µm. *, P<0.05. NS, normal saline; NC, normal control; CP/CPPS-A, type IIIA chronic prostatitis/chronic pelvic pain syndrome; CP/CPPS-A + US, ultrasonic treatment in the CP/CPPS-A; MPO, myeloperoxidase.

9). Zhuoqi Liu et al. Screening of Immunosuppressive Factors for Identifying Breast Cancer Malignant Phenotypes Using mRNA Microarray Datasets. Preprints 2016; 2016090124

10). Kang K et al. FGF21 Attenuates Neurodegeneration though Modulating Neuroinflammation and Oxidant-stress. Biomed Pharmacother 2020 Sep;129:110439. (PubMed: 32768941)

Application: IHC    Species: mouse    Sample: brains

Fig. 5. |FGF21 attenuates neurodegeneration through anti-inflammation in aging mice (n = 7-8/group). (D) The injury levels were exhibited by H&E staining (10X magnification, bar = 100 μm) and IL6, IL8 levels were exhibited by immunohistochemistry (40X magnification, bar = 20 μm) in the brains of each group mice. The FGF21 (1.0 mg/kg) and metformin (20 mg/kg)were used. The data were performed using one-way analysis of variance (ANOVA), followed by the two-tailed t test. Significant as compared to young mice. *p<0.05.Significant as compared to aging mice. #p<0.05.

Application: WB    Species: mouse    Sample: brains

Fig. 3. |FGF21 attenuates the expression of NF-κB, Iba1, IL6 and IL8 in the brains of diabetic mice (n = 10/group). (A)The IL6 levels of each group mice were exhibited by immunohistochemistry (40X magnification, bar = 20 μm). (B) The levels of NF-κB, Iba1, IL6 and IL8 in the brains were measured by Western blot.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.